MISS KARN SAU MENG

Name
MISS KARN SAU MENG
Nationality
Malaysia
Gender
Female
Age
55
Designation
Audit Committee
Directorate
Independent and Non Executive
Working Experience
Karen Karn is the Principal Consultant in Addworth Solutions. She has over 30 years of working
experience in management and leadership positions, business systems, and processes, business
planning and budgeting, HR management, appraisals, and performance management.
Prior to her consultancy, Karen started her career as an auditor in CH Lim & Co for 3 years, moving on
to lead an accounting team in The Crown Princess Hotel in the AP Land group of companies for another
4 years. She later worked in several roles as an Accountant and Logistics Manager in Astra
Pharmaceuticals Sdn Bhd, a wholly owned Swedish multinational pharmaceutical company for 6 years.
After a merger, she became the Finance Manager for AstraZeneca Sdn Bhd, a wholly owned subsidiary
of AstraZenca PLC in the United Kingdom. In the merger she oversaw the merging of accounting
systems, policies, and business processes. She had responsibility over the accounting, purchasing,
and logistics teams in Malaysia and also had a short 3-month stint in South Africa filling a Finance
Manager vacancy. Karen was later promoted as the Chief Financial Officer and the Finance and
Administration Director of the AstraZeneca subsidiaries in Malaysia and Singapore, managing
Accounting, Logistics, Information Technology and Administration teams in both countries. She
managed the transfer pricing negotiations for the companies and worked closely with the Managing
Director leading the Executive team in the Sabarns-Oxley US audit. She also oversaw the
implementation of SAP (ERP) system and was part of the Malaysia-Singapore steering committee for
the regional SAP project for the AstraZeneca group of subsidiaries in Southeast Asia. Karen was also
a Board member and Director in AstraZeneca Sdn Bhd. Karen was with AstraZeneca for 6 years before
moving on to setting up her own consultancy firm in 2007.
Directorship of Public Companies
No.
Family Relationship
No.
Interest
No.
Conflict of Interest
No.
Direct (units)
20,000
Direct (%)
0.00%
Indirect (units)
0
Indirect (%)
0.00%
Total (units)
20,000
Total (%)
0.00%
Date of Notice
29-Mar-2022

Details of Changes
Securities After Change
Transactions
Ann. Date Name Details of Changes Securities After Changes
Date Type No. of Shares Price Direct (%) Indirect (%) Total (%)

Changes
Ann. Date Date Type Name Title View
Related Stocks
Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment